Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Simon F. Scrace"'
Autor:
David A. Robinson, Claire L. Nunns, Christopher J. Northfield, Jonathan D. Moore, Christine M. Richardson, Ben Davis, James Brooke Murray, Victoria Oldfield, Pawel Dokurno, Simon F. Scrace, Lisa Baker, Stuart C. Ray, Christophe Fromont, Allan E. Surgenor, Natalia Matossova, Andrew John Potter, Christopher J. Bryant
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:6483-6488
Pin1 is an emerging oncology target strongly implicated in Ras and ErbB2-mediated tumourigenesis. Pin1 isomerizes bonds linking phospho-serine/threonine moieties to proline enabling it to play a key role in proline-directed kinase signalling. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb408e6192ebe8b2b837d4cc02d11d9
https://doi.org/10.1016/j.bmcl.2010.09.063
https://doi.org/10.1016/j.bmcl.2010.09.063
Autor:
Kim Hoenderdos, Cristina Ghirelli, Christopher J. Lowe, Nicola McCarthy, Jonathan D. Moore, Thibault Laurent, Simon F. Scrace
Publikováno v:
Cancer Research. 77:4123-4123
A major focus in immuno-oncology research is finding new immuno-oncology targets, including those that alter the character and frequency of T-cell-mediated anti-tumour responses. Screens using CRISPR (Clustered Regularly Interspaced Short Palindromic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81a5dac7d6a3edd67a9fad38a2052f2b
https://doi.org/10.1158/1538-7445.am2017-4123
https://doi.org/10.1158/1538-7445.am2017-4123
Autor:
Jonathan D. Moore, Lydia Kifle, Janine Steiger, Tabasum Huseni, Lauren Thibault, Felicia Zhao, Nava Almog, Christopher E. Lowe, Simon F. Scrace, Sujatha Kumar, Kim Hoenderdos, Anatoly Myaskovsky, An Frank, Nicola J. McCarthy, Christina Ghirelli
Publikováno v:
Cancer Immunology Research. 5:B66-B66
Horizon is establishing a powerful in vitro immuno-oncology platform with the capability to identify combinations of agents that will synergise with checkpoint inhibitors, determine methods for making safer and more effective cell therapies and find
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52bb63b8c8324d8136fd8f4026b6e6c7
https://doi.org/10.1158/2326-6074.tumimm16-b66
https://doi.org/10.1158/2326-6074.tumimm16-b66
Autor:
Sarah Denny, Andrew Cansfield, Philip Stephen Jackson, Jonathan D. Moore, Douglas S. Williamson, Peter Kierstan, Lan-Zhen Wang, Simon F. Scrace, Joanne Wayne, Andrea M. Lockie, Nicola J. Curtin, Carol Bentley, David R. Newell, Jenifer Borgognoni
Publikováno v:
Cell cycle (Georgetown, Tex.). 7(24)
Transient treatment with small molecule CDK inhibitors is toxic to cancer cells and leads to depletion of anti-apoptotic proteins and Chk1, coupled with DNA damage and induction of apoptosis. Here we have examined, which of these phenomena are necess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8f0d6ba4c8ba95f6dc5729a377d973
https://pubmed.ncbi.nlm.nih.gov/19066455
https://pubmed.ncbi.nlm.nih.gov/19066455
Autor:
Elpida Tsonou, Paul Russell, Steffen Lawo, Tim M. Scales, Ceri M. Wiggins, Simon F. Scrace, Jonathan D. Moore, Julie A Wickenden
Publikováno v:
Cancer Research. 75:700-700
No molecularly targeted therapy has yet been identified for KRAS mutant cancers. As oncogenic mutations reduce RAS enzymatic activity, classic small molecule approaches are ineffective, hence most work has focussed on drugging RAS-effector pathways.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a59c7f16bd990b07840c5806f732cb8
https://doi.org/10.1158/1538-7445.am2015-700
https://doi.org/10.1158/1538-7445.am2015-700
Autor:
Claire L. Nunns, Jonathan D. Moore, Simon F. Scrace, David A. Robinson, Lisa Baker, Pawel Dokurno, James Brooke Murray, Natalia Matassova, Louisa Gueritz, Andrew J. Potter, Stuart C. Ray, Christine M. Richardson, Ben Davis, Christopher J. Bryant, Allan E. Surgenor
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:e1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd132975bf55cc29f6828ab29cc2b55f
https://doi.org/10.1016/j.bmcl.2010.06.114
https://doi.org/10.1016/j.bmcl.2010.06.114
Autor:
Andrew Massey, Michael Wood, Simon Bedford, Paul Webb, Nicolas Foloppe, Allan M. Jordan, Martin J. Drysdale, Stuart C. Ray, Simon F. Scrace, Andrea Fiumana, Jennifer Borgognoni, Stephen Stokes, Helen Browne
Publikováno v:
Molecular Cancer Therapeutics. 8:C207-C207
Conventional chemotherapeutic agents such as gemcitabine, cisplatin or irinotecan induce DNA damage and activate cell cycle checkpoints. P53 defective tumors lack a functional G1 checkpoint and rely heavily on the S and G2 checkpoints, and the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a367f39e352915e0d917c5103b8a30
https://doi.org/10.1158/1535-7163.targ-09-c207
https://doi.org/10.1158/1535-7163.targ-09-c207